The malignant melanoma market has become increasingly crowded in recent years with novel treatments expanding therapy options for patients and segmenting the market according to BRAF mutational status. The introduction of immune checkpoint inhibitors such as Merck & ;s Keytruda and Bristol-Myers Squibb’s Opdivo has led to their domination of this market. The treatment algorithm will continue to evolve, with the entry of several agents into the underpenetrated and high opportunity resectable setting, the advent of triplet BRAF/MEK/immune checkpoint inhibitor combinations in the unresectable or metastatic setting, and the market entry of IDO-1 inhibitors in combination with PD-1 inhibitors. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake. 
 

Questions Answered: 

  • How large are the clinically and commercially relevant drug-treatable malignant melanoma populations and how will drug-treatment rates change (if at all) over time? 
  • What is the current state of treatment in malignant melanoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled? 
  • What pipeline products are most promising, and what sales/uptake could they secure in the malignant melanoma market? What does the early phase pipeline look like? 
  • What are the drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period? 
     

Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /...

View Details

Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

View Details

Malignant Melanoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of ma...

View Details